array(3) {
["company_details"]=>
array(13) {
["name"]=>
string(29) "Regeneron Pharmaceuticals Inc"
["slug"]=>
string(38) "c469a-us-regeneron-pharmaceuticals-inc"
["logo"]=>
string(84) "https://images.businessradar.com/linkedin_logos/b5187988-884a-43b7-980d-e1555548ab77"
["description"]=>
string(868) "At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in.
Please visit www.regeneron.com/social-media-terms for information on how to engage with us on social media.
An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media. "
["address_street"]=>
string(25) "777 Old Saw Mill River Rd"
["address_place"]=>
string(9) "Tarrytown"
["address_region"]=>
string(8) "New York"
["founding_date"]=>
string(10) "1988-02-08"
["website_domain"]=>
string(13) "regeneron.com"
["website_url"]=>
string(25) "https://www.regeneron.com"
["industry_codes"]=>
array(1) {
[0]=>
string(27) "Pharmaceutical Preparations"
}
["employee_count"]=>
int(10368)
["article_count"]=>
int(2438)
}
["articles"]=>
array(9) {
[0]=>
array(7) {
["title_en"]=>
string(40) "REGENERON - Where are new opportunities?"
["snippet_en"]=>
string(121) "Regeneron shares have been under pressure for several weeks. How does this downward movement fit into the bigger picture?"
["url"]=>
string(70) "https://stock3.com/news/regeneron-wo-bieten-sich-neue-chancen-14484856"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/b2e49775-85a2-4761-b202-0f94c423d8ec"
["source"]=>
string(10) "stock3.com"
["publication_date"]=>
string(10) "2024-04-16"
["categories"]=>
array(1) {
[0]=>
string(12) "Stock Market"
}
}
[1]=>
array(7) {
["title_en"]=>
string(90) "Regeneron Stock Under Microscope After DOJ Price Reporting Complaint—Key Levels to Watch"
["snippet_en"]=>
string(169) "Regeneron shares were lower in premarket trading Thursday after the DOJ filed a complaint accusing the drugmaker of fraudulent price reporting. Monitor these key levels."
["url"]=>
string(105) "https://www.investopedia.com/regeneron-stock-under-microscope-after-doj-price-reporting-complaint-8629923"
["image_url"]=>
NULL
["source"]=>
string(16) "investopedia.com"
["publication_date"]=>
string(10) "2024-04-11"
["categories"]=>
array(3) {
[0]=>
string(12) "Stock Market"
[1]=>
string(24) "Stock Research & Ratings"
[2]=>
string(5) "Fraud"
}
}
[2]=>
array(7) {
["title_en"]=>
string(87) "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Ritholtz Wealth Management"
["snippet_en"]=>
string(256) "Ritholtz Wealth Management decreased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 2.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission."
["url"]=>
string(127) "https://www.defenseworld.net/2024/04/01/regeneron-pharmaceuticals-inc-nasdaqregn-shares-sold-by-ritholtz-wealth-management.html"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/b395be10-d1fb-4a93-a488-056eaf2d86bb"
["source"]=>
string(16) "defenseworld.net"
["publication_date"]=>
string(10) "2024-04-01"
["categories"]=>
array(5) {
[0]=>
string(11) "Regulations"
[1]=>
string(18) "General Investment"
[2]=>
string(12) "Stock Market"
[3]=>
string(24) "Stock Research & Ratings"
[4]=>
string(31) "Financial Update/Profit Warning"
}
}
[3]=>
array(7) {
["title_en"]=>
string(57) "3 Biotech Stocks to Buy for the Next Bull Run: March 2024"
["snippet_en"]=>
string(127) "These biotech stocks to buy are well positioned for growth, and will generate solid returns for investors in the next bull run."
["url"]=>
string(91) "https://investorplace.com/2024/03/3-biotech-stocks-to-buy-for-the-next-bull-run-march-2024/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/2b16bb66-c6fd-49ac-a01f-4de85e2522f7"
["source"]=>
string(17) "investorplace.com"
["publication_date"]=>
string(10) "2024-03-26"
["categories"]=>
array(3) {
[0]=>
string(18) "General Investment"
[1]=>
string(12) "Stock Market"
[2]=>
string(24) "Quarterly/Annual Figures"
}
}
[4]=>
array(7) {
["title_en"]=>
string(87) "Roche Holdings AG Basel ADR Common Stock (RHHBY) Stock: What Does the Chart Say Friday?"
["snippet_en"]=>
string(87) "Roche Holdings AG Basel ADR Common Stock (RHHBY) Stock: What Does the Chart Say Friday?"
["url"]=>
string(137) "https://www.investorsobserver.com/news/stock-update/roche-holdings-ag-basel-adr-common-stock-rhhby-stock-what-does-the-chart-say-friday-3"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/1896feb4-f5ff-418e-b5a2-212fdbed080f"
["source"]=>
string(21) "investorsobserver.com"
["publication_date"]=>
string(10) "2024-03-22"
["categories"]=>
array(4) {
[0]=>
string(24) "Stock Research & Ratings"
[1]=>
string(12) "Stock Market"
[2]=>
string(15) "Market Movement"
[3]=>
string(13) "Credit Rating"
}
}
[5]=>
array(7) {
["title_en"]=>
string(57) "Regeneron Pharmaceuticals Stock (REGN) - Today's Industry"
["snippet_en"]=>
string(110) "Latest news about Regeneron Pharmaceuticals stock. Regeneron Pharmaceuticals complete company facts from Di.se"
["url"]=>
string(42) "https://www.di.se/bors/aktier/regn-251133/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/6e671b50-b210-466a-8e7c-d20bc438bc93"
["source"]=>
string(5) "di.se"
["publication_date"]=>
string(10) "2024-03-08"
["categories"]=>
array(3) {
[0]=>
string(12) "Going Public"
[1]=>
string(12) "Stock Market"
[2]=>
string(24) "Stock Research & Ratings"
}
}
[6]=>
array(7) {
["title_en"]=>
string(68) "The biotech $100-billion Club: Meet the 14 most valuable drug makers"
["snippet_en"]=>
string(138) "Discover the biotech leaders with a market capitalization exceeding $100 billion, driving innovation and shaping tomorrow's breakthroughs."
["url"]=>
string(75) "https://www.labiotech.eu/best-biotech/biotech-companies-highest-market-cap/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/e5ed3a68-784f-4a3c-815d-3673c1eb3930"
["source"]=>
string(12) "labiotech.eu"
["publication_date"]=>
string(10) "2024-03-05"
["categories"]=>
array(2) {
[0]=>
string(12) "Stock Market"
[1]=>
string(31) "Financial Update/Profit Warning"
}
}
[7]=>
array(7) {
["title_en"]=>
string(108) "Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Stock Is Going Strong: Is the Market Following Fundamentals?"
["snippet_en"]=>
string(120) "Regeneron Pharmaceuticals (NASDAQ:REGN) has had a great run on the share market with its stock up by a significant 20..."
["url"]=>
string(87) "https://finance.yahoo.com/news/regeneron-pharmaceuticals-inc-nasdaq-regn-130019594.html"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/4f3da250-a78a-44f9-827d-452c8f1cf48d"
["source"]=>
string(9) "yahoo.com"
["publication_date"]=>
string(10) "2024-02-29"
["categories"]=>
array(2) {
[0]=>
string(12) "Stock Market"
[1]=>
string(15) "Market Movement"
}
}
[8]=>
array(7) {
["title_en"]=>
string(86) "Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day"
["snippet_en"]=>
string(157) "Shares of Regeneron Pharmaceuticals Inc. slipped 0.69% to $940.48 Tuesday, on what proved to be an all-around dismal trading session for the stock market,..."
["url"]=>
string(145) "https://www.marketwatch.com/data-news/regeneron-pharmaceuticals-inc-stock-outperforms-competitors-despite-losses-on-the-day-10a2f390-5ce06124e555"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/ce0eb208-fffe-4f22-868f-2bef6909c643"
["source"]=>
string(15) "marketwatch.com"
["publication_date"]=>
string(10) "2024-02-13"
["categories"]=>
array(4) {
[0]=>
string(12) "Stock Market"
[1]=>
string(24) "Stock Research & Ratings"
[2]=>
string(15) "Market Movement"
[3]=>
string(24) "Quarterly/Annual Figures"
}
}
}
["category_annotations"]=>
array(30) {
[0]=>
array(2) {
["name"]=>
string(12) "Stock Market"
["count"]=>
int(197)
}
[1]=>
array(2) {
["name"]=>
string(8) "Epidemic"
["count"]=>
int(193)
}
[2]=>
array(2) {
["name"]=>
string(5) "Legal"
["count"]=>
int(152)
}
[3]=>
array(2) {
["name"]=>
string(24) "Quarterly/Annual Figures"
["count"]=>
int(100)
}
[4]=>
array(2) {
["name"]=>
string(5) "Award"
["count"]=>
int(95)
}
[5]=>
array(2) {
["name"]=>
string(17) "Academic Research"
["count"]=>
int(83)
}
[6]=>
array(2) {
["name"]=>
string(5) "Event"
["count"]=>
int(70)
}
[7]=>
array(2) {
["name"]=>
string(13) "Collaboration"
["count"]=>
int(61)
}
[8]=>
array(2) {
["name"]=>
string(18) "Expansion & Growth"
["count"]=>
int(51)
}
[9]=>
array(2) {
["name"]=>
string(10) "Litigation"
["count"]=>
int(50)
}
[10]=>
array(2) {
["name"]=>
string(11) "Acquisition"
["count"]=>
int(46)
}
[11]=>
array(2) {
["name"]=>
string(18) "General Investment"
["count"]=>
int(44)
}
[12]=>
array(2) {
["name"]=>
string(5) "R & D"
["count"]=>
int(35)
}
[13]=>
array(2) {
["name"]=>
string(24) "Stock Research & Ratings"
["count"]=>
int(35)
}
[14]=>
array(2) {
["name"]=>
string(14) "Issuing Shares"
["count"]=>
int(34)
}
[15]=>
array(2) {
["name"]=>
string(46) "Management of Legal and Regulatory Environment"
["count"]=>
int(33)
}
[16]=>
array(2) {
["name"]=>
string(12) "Board Change"
["count"]=>
int(33)
}
[17]=>
array(2) {
["name"]=>
string(15) "Deals & Tenders"
["count"]=>
int(32)
}
[18]=>
array(2) {
["name"]=>
string(21) "Competitive Behaviour"
["count"]=>
int(31)
}
[19]=>
array(2) {
["name"]=>
string(15) "Market Movement"
["count"]=>
int(31)
}
[20]=>
array(2) {
["name"]=>
string(14) "Product Review"
["count"]=>
int(31)
}
[21]=>
array(2) {
["name"]=>
string(31) "Financial Update/Profit Warning"
["count"]=>
int(29)
}
[22]=>
array(2) {
["name"]=>
string(27) "Business Model & Innovation"
["count"]=>
int(29)
}
[23]=>
array(2) {
["name"]=>
string(8) "Verdicts"
["count"]=>
int(29)
}
[24]=>
array(2) {
["name"]=>
string(14) "Product Launch"
["count"]=>
int(27)
}
[25]=>
array(2) {
["name"]=>
string(11) "Competition"
["count"]=>
int(26)
}
[26]=>
array(2) {
["name"]=>
string(13) "Data Security"
["count"]=>
int(24)
}
[27]=>
array(2) {
["name"]=>
string(24) "Access and affordability"
["count"]=>
int(23)
}
[28]=>
array(2) {
["name"]=>
string(11) "Sponsorship"
["count"]=>
int(20)
}
[29]=>
array(2) {
["name"]=>
string(8) "Politics"
["count"]=>
int(20)
}
}
}
c469a-us-regeneron-pharmaceuticals-inc
Regeneron Pharmaceuticals Inc
Location
New York
Founded
1988-02-08
Website
https://www.regeneron.com
Articles
2438 Articles
Category
Pharmaceutical Preparations
Description
At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in.
Please visit www.regeneron.com/social-media-terms for information on how to engage with us on social media.
An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media.
Regeneron shares were lower in premarket trading Thursday after the DOJ filed a complaint accusing the drugmaker of fraudulent price reporting. Monitor these key levels.
Ritholtz Wealth Management decreased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 2.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission.
Shares of Regeneron Pharmaceuticals Inc. slipped 0.69% to $940.48 Tuesday, on what proved to be an all-around dismal trading session for the stock market,...
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
